For patients with little LDL receptor function, LDL receptor-independent treatment targeting ANGPTL3 through monoclonal therapies are now available, or in the future, antisense/small interfering RNA-based approaches offer alternative approaches.

Editors

Editor-in-Chief
Valentin Fuster, MD, PhD, MACC

CME Editor
Ragavendra R. Baliga, MD

Authors
Julia Brandts, MD

Kausik K. Ray, BSC (HONS), MBCHB, MD, MPHIL (CANTAB) 

Important Dates

Date of Release: October 25, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: October 24, 2022